Sensyne Health launches new app for diabetes patients
Sensyne Health
0.35p
16:50 17/06/22
Clinical artificial intelligence (AI) company Sensyne Health announced the development of a new software application for people with diabetes on Wednesday, branded ‘DBm-Health’.
FTSE AIM All-Share
744.79
16:25 19/04/24
Health Care Equipment & Services
11,690.05
16:40 19/04/24
The AIM-traded firm said the product’s intended user population would cover all stages of the disease, including individuals at risk of developing diabetes, as well as those with a diagnosis of pre-diabetes, type 1 or type 2.
DBm-Health was designed to connect people with diabetes with the clinician responsible for their care, the company explained, and said that unlike other apps, it would provide their clinician with information on the status of the patient and whether any intervention could be required.
It said the app would connect patients in need of regular blood glucose self-monitoring with their clinicians, adding that it was developed in response to success of ‘GDm-Health’ for women with diabetes in pregnancy, as well as increasing demand from clinicians for new digital technologies, particularly during the Covid-19 pandemic.
The company said it was working with three NHS trusts to deploy DBm-Health in an initial UK launch, with a US commercial launch planned for later in the current financial year.
“I am very proud of the speed at which the Sensyne team has responded to this clinical need and the clear demonstration of the scalability of the platform we have built at Sensyne,” said chief executive officer Lord Drayson.
“We are acutely aware of the concerns of diabetic patients and the people that care for them, and of the additional burden that Covid-19 has brought to the management of this complex and potentially life-threatening condition.
“Rapid uptake of DBm-Health in the UK has the potential to make a significant difference to diabetes care in the NHS and provides a strong foundation to launch DBm-Health in the US later this financial year.”
At the close on Wednesday, shares in Sensyne Health were up 24.48% at 59.75p.